Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2012 - 2026)

Jazz Pharmaceuticals' Deferred Taxes history runs 15 years deep, the most recent figure standing at -$66.2 million for Q1 2026.

• In Q1 2026, Deferred Taxes fell 51.14% year-over-year to -$66.2 million; the TTM figure through Mar 2026 stood at -$467.4 million (down 151.62% YoY), while the FY2025 annual figure was -$445.0 million, down 113.59% from the prior year.
• Deferred Taxes for Q1 2026 stood at -$66.2 million, down from -$63.3 million in the prior quarter.
• The five-year high for Deferred Taxes was -$2.4 million in Q4 2024, with the low at -$271.4 million in Q3 2025.
• The 5-year median for Deferred Taxes is -$66.1 million (2023), against an average of -$74.8 million.
• The sharpest annual moves came in 2024 and 2025: Deferred Taxes soared 93.44% in 2024, then plunged 2588.28% in 2025.
• Jazz Pharmaceuticals' Deferred Taxes stood at -$145.4 million in 2022, then jumped by 75.31% to -$35.9 million in 2023, then jumped by 93.44% to -$2.4 million in 2024, then slumped by 2588.28% to -$63.3 million in 2025, then retreated by 4.57% to -$66.2 million in 2026.
• Business Quant data shows JAZZ's Deferred Taxes at -$66.2 million in Q1 2026, -$63.3 million in Q4 2025, and -$271.4 million in Q3 2025.